ZBH icon

Zimmer Biomet

93.32 USD
-1.63
1.72%
At close Jul 30, 4:00 PM EDT
After hours
93.32
+0.00
0.00%
1 day
-1.72%
5 days
-4.04%
1 month
2.31%
3 months
-9.44%
6 months
-15.64%
Year to date
-10.66%
1 year
-16.21%
5 years
-30.50%
10 years
-8.33%
 

About: Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Employees: 17,000

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 11 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

102% more call options, than puts

Call options by funds: $69.9M | Put options by funds: $34.6M

33% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 12 (+3) [Q1 2025]

7% more capital invested

Capital invested by funds: $19.2B [Q4 2024] → $20.6B (+$1.43B) [Q1 2025]

0.22% more ownership

Funds ownership: 91.4% [Q4 2024] → 91.61% (+0.22%) [Q1 2025]

9% less first-time investments, than exits

New positions opened: 89 | Existing positions closed: 98

3% less funds holding

Funds holding: 1,011 [Q4 2024] → 985 (-26) [Q1 2025]

25% less repeat investments, than reductions

Existing positions increased: 289 | Existing positions reduced: 385

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$95
2%
upside
Avg. target
$106
14%
upside
High target
$125
34%
upside

11 analyst ratings

positive
55%
neutral
45%
negative
0%
Evercore ISI Group
Vijay Kumar
3%upside
$96
In-Line
Maintained
8 Jul 2025
Canaccord Genuity
William Plovanic
8%upside
$101
Hold
Maintained
12 May 2025
JMP Securities
David Turkaly
34%upside
$125
Market Outperform
Maintained
7 May 2025
Goldman Sachs
David Roman
11%upside
$104
Neutral
Maintained
6 May 2025
Raymond James
Jayson Bedford
11%upside
$104
Outperform
Maintained
6 May 2025

Financial journalist opinion

Based on 5 articles about ZBH published over the past 30 days

Positive
Seeking Alpha
1 week ago
Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA
I reiterate my Buy rating on Zimmer Biomet Holdings, Inc., setting a fair value of $133 per ZBH share due to strong business acceleration opportunities. The Monogram Technologies acquisition could significantly enhance Zimmer's knee robotics, positioning it to better compete with Stryker through advanced autonomous technology. Paragon 28's integration is on track and expected to boost Zimmer's foot and ankle portfolio, contributing to topline growth in a fast-expanding market.
Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA
Positive
Zacks Investment Research
1 week ago
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
Neutral
Business Wire
2 weeks ago
MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Monogram Technologies Inc. (NasdaqCM: MGRM) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Monogram will receive an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right entitling the holder to receive u.
MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM
Neutral
CNBC Television
2 weeks ago
Final Trades: Uber, Delta, Zimmer Holdings and Boeing
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Uber, Delta, Zimmer Holdings and Boeing
Neutral
PRNewsWire
3 weeks ago
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results
WARSAW, Ind. , July 9, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Thursday, August 7, 2025 at 8:30 a.m.
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results
Neutral
CNBC Television
1 month ago
New vaccine panel meeting underway
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.
New vaccine panel meeting underway
Negative
Zacks Investment Research
1 month ago
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
Neutral
PRNewsWire
2 months ago
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025
WARSAW, Ind. , May 30, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2025.
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025
Neutral
PRNewsWire
2 months ago
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas
WARSAW, Ind. , May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas.
Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas
Neutral
PRNewsWire
2 months ago
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m.
Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Charts implemented using Lightweight Charts™